Menu
← Oncology Approval Tracker
FDA DECISION ·
Nubeqa + docetaxel
darolutamide plus docetaxel · Bayer
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic hormone-sensitive prostate cancer receiving darolutamide together with docetaxel.
LAMPGEN ANALYSIS
Why it matters
The 2022 decision is for the docetaxel combination in the hormone-sensitive setting.
What research teams should watch
Confirm metastatic and hormone-sensitive status and align androgen deprivation, docetaxel and oral therapy workflows.
PRIMARY RECORDS